[go: up one dir, main page]

UA70925C2 - Спосіб лікування естрогенстимульованого раку - Google Patents

Спосіб лікування естрогенстимульованого раку

Info

Publication number
UA70925C2
UA70925C2 UA2000020847A UA00020847A UA70925C2 UA 70925 C2 UA70925 C2 UA 70925C2 UA 2000020847 A UA2000020847 A UA 2000020847A UA 00020847 A UA00020847 A UA 00020847A UA 70925 C2 UA70925 C2 UA 70925C2
Authority
UA
Ukraine
Prior art keywords
estrogen
disorders
treatment
prevention
dependent diseases
Prior art date
Application number
UA2000020847A
Other languages
English (en)
Russian (ru)
Inventor
Доналд П. Макдоннелл
Джон Норріс
Керолайн Коннор
Ашіні Віджаяратне
Original Assignee
Дюк Юнівесіті
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дюк Юнівесіті filed Critical Дюк Юнівесіті
Publication of UA70925C2 publication Critical patent/UA70925C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Винахід стосується лікування естрогензалежних захворювань, зокрема раку, стійкого до тамоксифену, ідоксифену, ралоксифену або ІСІ182780.
UA2000020847A 1997-08-15 1998-08-14 Спосіб лікування естрогенстимульованого раку UA70925C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5588197P 1997-08-15 1997-08-15
PCT/US1998/016864 WO1999008682A1 (en) 1997-08-15 1998-08-14 A method of preventing or treating estrogen-dependent diseases and disorders

Publications (1)

Publication Number Publication Date
UA70925C2 true UA70925C2 (uk) 2004-11-15

Family

ID=22000784

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2000020847A UA70925C2 (uk) 1997-08-15 1998-08-14 Спосіб лікування естрогенстимульованого раку

Country Status (21)

Country Link
US (1) US7307102B2 (uk)
EP (1) EP1019057B1 (uk)
JP (1) JP2001515038A (uk)
KR (1) KR20010022956A (uk)
CN (1) CN1275911A (uk)
AT (1) ATE411016T1 (uk)
AU (1) AU757206B2 (uk)
BR (1) BR9811946A (uk)
CA (1) CA2301032C (uk)
CZ (1) CZ300929B6 (uk)
DE (1) DE69840126D1 (uk)
EE (1) EE200000077A (uk)
ES (1) ES2312189T3 (uk)
HU (1) HUP0002852A3 (uk)
IL (1) IL134445A0 (uk)
NO (1) NO20000752L (uk)
NZ (1) NZ502738A (uk)
PL (1) PL338555A1 (uk)
RU (1) RU2214236C2 (uk)
UA (1) UA70925C2 (uk)
WO (1) WO1999008682A1 (uk)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
JP2003520758A (ja) * 1998-06-12 2003-07-08 リガンド・ファーマシューティカルズ・インコーポレイテッド 抗エストロゲン耐性乳癌のｒｘｒモジュレーターを用いた処置
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
JP4790178B2 (ja) * 1999-07-06 2011-10-12 アンドルシェルシュ・インコーポレイテッド 体重増加の処置方法および／または抑制方法
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6528681B2 (en) 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
WO2002002006A1 (en) * 2000-07-05 2002-01-10 Seely Andrew J E Method and apparatus for multiple patient parameter variability analysis and display
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20020164581A1 (en) * 2001-03-12 2002-11-07 Chawnshang Chang Methods for identifying compounds that do not attenuate the protective effects of estrogen
JP2005528320A (ja) 2001-08-11 2005-09-22 ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー 選択的なエストロゲン受容体モジュレーター
WO2006007314A1 (en) 2004-06-23 2006-01-19 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
CA2584396A1 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
CN101129344A (zh) * 2004-12-08 2008-02-27 西来昂诊疗公司 治疗与视黄醇有关的疾病的方法、分析和组合物
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
CN101939738A (zh) 2007-10-03 2011-01-05 渥太华医院研究所 用于监控一个或多个器官的随着时间过去的生理参数变异性的方法和装置
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
US8343996B2 (en) 2008-11-13 2013-01-01 Astrazeneca Ab Azaquinolinone derivatives and uses thereof
PH12012502419A1 (en) 2010-06-10 2022-03-21 Seragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CN102532073A (zh) * 2011-12-30 2012-07-04 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
WO2013142266A1 (en) 2012-03-20 2013-09-26 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
HRP20221462T1 (hr) * 2015-12-09 2023-01-20 The Board Of Trustees Of The University Of Illinois Selektivni nishodni regulatori receptora estrogena na bazi benzotiofena
EP3658527A4 (en) * 2017-07-28 2021-04-07 Recurium IP Holdings, LLC ACRYLIC ACID ANALOGUES

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (uk) 1962-09-13
GB1029221A (en) 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
GB1079747A (en) 1965-07-07 1967-08-16 Ici Ltd Alkene derivatives
US3637856A (en) 1965-07-12 1972-01-25 Ici Ltd Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof
GB1128379A (en) 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
GB1560274A (en) 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
US4206234A (en) 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
DE2860900D1 (en) 1977-08-22 1981-11-05 Ici Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3060722D1 (en) 1979-05-15 1982-09-30 Ici Plc 1-hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them
HU178253B (en) 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
CA1229604A (en) 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US4859695A (en) 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
CA1289570C (en) 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
DE3736682A1 (de) 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5119827A (en) 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
EP0551434B1 (en) 1990-10-01 1995-11-15 The Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
AU659157B2 (en) 1991-04-30 1995-05-11 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylene derivative and pharmaceutical preparation containing the same
EP0660821B1 (en) 1992-09-15 1998-01-21 Merrell Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5681835A (en) * 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
HUP0002852A2 (hu) 2001-10-28
NO20000752D0 (no) 2000-02-15
EP1019057A1 (en) 2000-07-19
DE69840126D1 (de) 2008-11-27
CZ2000531A3 (en) 2001-05-16
BR9811946A (pt) 2000-08-22
AU757206B2 (en) 2003-02-06
CZ300929B6 (cs) 2009-09-16
AU8906398A (en) 1999-03-08
PL338555A1 (en) 2000-11-06
EP1019057A4 (en) 2006-06-14
NO20000752L (no) 2000-02-15
WO1999008682A1 (en) 1999-02-25
EP1019057B1 (en) 2008-10-15
KR20010022956A (ko) 2001-03-26
CA2301032C (en) 2009-01-13
IL134445A0 (en) 2001-04-30
ATE411016T1 (de) 2008-10-15
CA2301032A1 (en) 1999-02-25
EE200000077A (et) 2000-12-15
US20030232795A1 (en) 2003-12-18
CN1275911A (zh) 2000-12-06
ES2312189T3 (es) 2009-02-16
RU2214236C2 (ru) 2003-10-20
NZ502738A (en) 2002-06-28
US7307102B2 (en) 2007-12-11
HUP0002852A3 (en) 2001-11-28
JP2001515038A (ja) 2001-09-18

Similar Documents

Publication Publication Date Title
UA70925C2 (uk) Спосіб лікування естрогенстимульованого раку
MX9700118A (es) Metodo para inhibir metastasis de cancer mediante administracion oral de pectina citrica modificada soluble.
PT1955700E (pt) Tratamento terap?utico de doen?as associadas ao receptor de androg?nios
HK1022301A1 (en) Conjugates of cisdocosahexaenoic acid and paclitaxel
PL330496A1 (en) Methods of and compositions for treating and preventing tumours, disorders associated with tumours as well as cachexy
AU2207000A (en) Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
GB9815177D0 (en) Treatment of skin disorders
WO2003103585A3 (en) METHODS OF TREATING ANGIOGENESIS, TUMOR GROWTH AND METASTASES
MXPA04003674A (es) Uso mejorado de compuesto antitumoral en terapia de cancer.
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
MD1569G2 (ro) Metodă de tratament al cancerului mamar în perioada preoperatorie
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
MX9601031A (es) Composicion farmaceutica para el tratamiento y prevencion del cancer de prostata.
IL139303A0 (en) Treatment of arthritis and other similar conditions
AU5434899A (en) Cancer treatment
UA34368A (uk) Спосіб лікування рака молочної залози
AP2000001958A0 (en) Paroxetine 10-camphorsulfornate for treatment of CNS disorders.
WO1990011078A8 (en) Regional chemotherapy with 4-hydroperoxycyclophosphamide
UA36385A (uk) Спосіб лікування генералізованого пародонтиту
UA33531A (uk) Спосіб терапії шизофренії
UA34375A (uk) Спосіб лікування рака молочної залози
UA36251A (uk) Спосіб комплексної терапії простої шизофренії
UA33439A (uk) Спосіб інтенсивного лікування шизофренії